• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • 2MM Podcast
  • Write for us
  • Contact Us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • About
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Tools+
    • EvidencePulse™
    • HypeCheck™
    • NPI Registry Lookup
    • RVU Search
  • Pharma
  • AI Roundup
  • The Scan+
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • My account
    • Cart
    • Sign-in
2 Minute Medicine
  • About
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Tools+
    • EvidencePulse™
    • HypeCheck™
    • NPI Registry Lookup
    • RVU Search
  • Pharma
  • AI Roundup
  • The Scan+
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • My account
    • Cart
    • Sign-in
SUBSCRIBE
2 Minute Medicine
Subscribe
EvidencePulse™ by 2 Minute Medicine 2026 evidence scan 3 reports You asked top stroke trials 2026 Synthesizing medical evidence... Top 2026 stroke trial results: OCEANIC — ischemic stroke: 6.2% vs 8.4% OPTION* — mRS 0–1: 43.6% vs 34.2% ORIENTAL* — mRS 0–2: 58.6% vs 46.6% *Higher sICH in intervention arms Participants randomizedN OCEANIC 12,327 OPTION 570 ORIENTAL 564 Ask about guidelines or landmark trials... ↑ Try EvidencePulse™ Ask the evidence.
Get the signal.
Try it now → Physician-trained medical AI by 2 Minute Medicine
Home The Classics Radiology Classics

Breast density increases the risk of cancer and hinders mammographic detection [Classics Series]

byDeepti Shroff
August 11, 2022
in Radiology Classics, The Classics
Reading Time: 4 mins read
ABCD2 Score: Predicting Early Stroke Risk After Transient Ischemic Attack (TIA) [Classics Series]
Share on FacebookShare on Twitter

This study summary is an excerpt from the book 2 Minute Medicine’s The Classics in Medicine: Summaries of the Landmark Trials

1. Women with mammographic density obscuring more than 75% of the imaged breast demonstrated a significantly increased risk of breast cancer detected either by screening or within 12 months of a negative screening examination, compared to those with density in less than 10% of the mammogram.

2. The increase in risk of breast cancer in women with dense breasts was greatest in younger women. In this demographic, 25% of all detected cancers were attributable to density in at least 50% of the mammogram.

Original Date of Publication: January 2007

Study Rundown: Mammography is an X-ray based modality, visualizing the various tissues of the breast based on their inherent attenuation properties. Fat appears radiolucent, while epithelial and stromal tissues appear radiodense. As the relative proportion between these tissues shifts away from fat, the breast becomes increasingly “dense” on mammography. As many tumors may also appear radiodense, they may be hidden by the predominance of stroma within a dense breast, subsequently hindering early detection, while that increased density may itself be a risk factor for oncogenesis. Unfortunately, this interaction between breast density and the ability to detect cancers on screening previously confounded research regarding the risks associated with mammographic density. Cancer risk would be underestimated if based solely on those tumors detected at screening due to an omission of those masked by breast density, while risk would be overestimated if based solely on cancers detected by alternate means, as it would focus only on those missed at screening. The present study attempted to better estimate the true risk of mammographic density as it relates to breast cancer by determining the risk both at the time of screening and thereafter among women with quantified breast density from three large national case-control studies. Women with density in 75% or more of the mammogram demonstrated a significantly increased risk of breast cancer compared to those with density in 10% or less of the mammogram both at the time of screening or by alternate means. This risk was found to persist for up to 8 years after initial screening. The attributable risk of cancer to breast density was most marked in younger women, for whom 26% of all detected cancers, and 50% of those detected within 1 year of a negative examination were attributable to density in at least 50% of the mammogram. This study established an accurate estimate of the incidence of breast cancers attributable to increased breast density by combining those data for those detected at screening and those detected up to 12 months after a negative screening examination, representing cancers likely present at the time of initial screening but obscured by mammographic density.

Click to read the study in NEJM

RELATED REPORTS

Historical redlining associated with lower breast cancer screening across urban neighborhoods

Cognitive behaviour therapy may be superior to bright light therapy for insomnia in women with breast cancer undergoing chemotherapy

Tumour microenvironment factors may influence cancer progression and response to tamoxifen (Nolvadex) in patients with estrogen receptor-positive and human epidermal growth factor receptor 2 breast cancer

In-Depth [case-control study]: This retrospective case-control study pooled data from three large mammographic screening programs in Canada, the National Breast Screening Study (NBSS), the Ontario Breast Screening Program (OBSP), and the Screening Mammography Program of British Columbia (SMPBC.) A total of 1114 case-control pairs were included (mean age 56.7±9.1 years). Case subjects had histologically verified invasive breast cancer, excluding those with cancers detected within 12 months of their first screening mammogram, while up to 10 control subjects were matched to each index case on the basis of age, body-mass index, pregnancy and menopause history, hormone-replacement use, family history of breast cancer, and quantification of mammographic density. Mammograms from each subject were submitted and independently classified into one of six quantified degrees of breast density (0%, <10%, 10 to <25%, 25 to <50%, 50 to <75%, and ³75%) by two radiologists and a single observer using a computer-assisted technique. Notably, the average percentage of mammographic density was 5.8% higher among case subjects than control subjects at baseline. Women below the median age of 56 years were 3 times more likely to have breasts with a mammographic density of ³50%. The combined odds ratio for the detection of breast cancer among women with ³75% mammographic density was 4.7 (95%CI 3.0-7.4) as compared to those with £10% density. For those cancers detected at screening, the odds ratio was 3.5 (95%CI 2.0-6.2), while it was 17.8 (95%CI 4.8-65.9) for those cancers detected within 12 months of a negative screening mammogram. For cancers detected over a year after the last negative screening mammogram, the odds ratio was 5.7 (95%CI 2.1-15.5). These increased risks were significantly associated with percentage of breast density at all time periods, up to 8 years after entry into the study (p <0.001). The attributable risk of breast cancer for a mammographic density of ³50% was 16% for all cancers, much of which was limited to the 12 months following screening, suggesting that tumor masking was the principal mechanism of risk, rather than rapid tumor growth.

Boyd NF, Guo H, Marin LJ, Sun L, Stone J, Fishell E, et al. Mammographic Density and the Risk and Detection of Breast Cancer. The New England Journal of Medicine. 2007 Jan 18;356(3):227–36.

©2022 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: Breast Cancermammographytumor growth
Previous Post

Detection of advanced colorectal neoplasia by CT colonography comparable to optical colonoscopy [Classics Series]

Next Post

Monoclonal antibody L9LS prevents malaria infection in adults

RelatedReports

Oncology

Historical redlining associated with lower breast cancer screening across urban neighborhoods

September 13, 2026
Sleep duration, sleepiness, chronotype have variable associations with teen self-regulation
Chronic Disease

Cognitive behaviour therapy may be superior to bright light therapy for insomnia in women with breast cancer undergoing chemotherapy

September 3, 2026
Variability in interpretation of breast biopsy slides associated with low verification of atypia and ductal carcinoma in situ
Chronic Disease

Tumour microenvironment factors may influence cancer progression and response to tamoxifen (Nolvadex) in patients with estrogen receptor-positive and human epidermal growth factor receptor 2 breast cancer

August 13, 2026
Sleep duration, sleepiness, chronotype have variable associations with teen self-regulation
Weekly Rewinds

2 Minute Medicine Rewind August 10, 2026

August 10, 2026
Next Post
Intrauterine Zika virus infection associated with significant fetal brain abnormalities

Monoclonal antibody L9LS prevents malaria infection in adults

ABCD2 Score: Predicting Early Stroke Risk After Transient Ischemic Attack (TIA) [Classics Series]

MRI offers an alternative to endoscopic assessment of disease activity and severity in ileocolonic Crohn’s disease [Classics Series]

Radiofrequency catheter ablation effective as first-line therapy for atrial fibrillation [RAAFT-2 trial]

Postoperative and nonoperative atrial fibrillation have a similar risk of associated thromboembolism

EvidencePulse™ by 2 Minute Medicine 2026 evidence scan 3 reports You asked top stroke trials 2026 Synthesizing medical evidence... Top 2026 stroke trial results: OCEANIC — ischemic stroke: 6.2% vs 8.4% OPTION* — mRS 0–1: 43.6% vs 34.2% ORIENTAL* — mRS 0–2: 58.6% vs 46.6% *Higher sICH in intervention arms Participants randomizedN OCEANIC 12,327 OPTION 570 ORIENTAL 564 Ask about guidelines or landmark trials... ↑ Try EvidencePulse™ Ask the evidence.
Get the signal.
Try it now → Physician-trained medical AI by 2 Minute Medicine

2MM+ All Access

Full details →
$4.99 /month

5-day free trial · cancel anytime

  • ✓100+ physician-written reports
  • ✓EvidencePulse™ + HypeCheck™
  • ✓Ad-free reading + newsletters
Start 5-day free trial

Then $4.99/month. Manage renewal in your account.

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Deficits in executive function are not universal among patients with alcohol use disorder
  • Choice of bicarbonate-buffered solution versus compound sodium lactate as the intraoperative crystalloid solution during abdominal surgery remains unclear
  • Artificial intelligence (AI)-based coronary calcium quantification successfully identified patients who could benefit from lipid-lowering therapy
License Content
Terms of Use | Disclaimer
Cookie Policy
Cleantalk Pixel
2MM+ All Access Full details →

The medical literature, distilled daily.

Monthly plan selected: $4.99 /month.

$4.99/month

5-day free trial · cancel anytime

Start 5-day free trial

Then $4.99/month. Manage renewal in your account.

Yearly plan selected: $49.90 /year.

$49.90/year

2 months free · only $4.16/month

Start 5-day free trial

Then $49.90/year. Manage renewal in your account.

Membership benefits

  • ✓100+ physician-written reports
  • ✓AI EvidencePulse™ + HypeCheck™
  • ✓Ad-free reading + newsletters

Already a member? Sign in

  • About
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Tools
    • EvidencePulse™
    • HypeCheck™
    • NPI Registry Lookup
    • RVU Search
  • Pharma
  • AI Roundup
  • The Scan
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • My account
    • Cart
    • Sign-in
No Result
View All Result

© 2026 2 Minute Medicine, Inc. - Physician-written medical news.